About Human Amylin Receptor 3 (AMY3) Stable Cell Line

Amylin Receptor 3 (AMY3) is a member of the calcitonin receptor family of Class B G protein-coupled receptors (GPCRs). AMY3 is formed through heterodimerization of the Calcitonin Receptor (CTR) with Receptor Activity-Modifying Protein 3 (RAMP3). This receptor complex functions as one of the primary receptors for amylin (islet amyloid polypeptide, IAPP), a peptide hormone co-secreted with insulin by pancreatic β-cells. Upon activation by amylin, AMY3 initiates signaling pathways that include stimulation of cAMP production, calcium mobilization, ERK/MAPK activation, and other intracellular signaling cascades involved in metabolic regulation and neuronal function.

AMY3 is expressed in the central nervous system, pancreas, gastrointestinal tract, and other tissues involved in energy homeostasis and metabolic regulation. Through its interaction with amylin, AMY3 contributes to the regulation of appetite, gastric emptying, glucagon secretion, and postprandial glucose control. Amylin receptor signaling also influences satiety pathways in the brain and has attracted considerable interest as a therapeutic target for obesity, diabetes, and neurodegenerative diseases. Recent studies have implicated amylin receptor signaling, including AMY3-mediated pathways, in Alzheimer's disease and other neurological disorders, expanding its relevance beyond metabolic disease research.

eEnzyme's Human AMY3 Stable Cell Line provides a reliable and reproducible cellular platform for investigating AMY3 receptor pharmacology and signaling mechanisms. The cell line enables quantitative assessment of amylin analogs, agonists, antagonists, peptide therapeutics, and novel receptor modulators through cAMP assays, calcium mobilization assays, reporter gene assays, and other GPCR functional screening platforms. Researchers can utilize this stable cell line for receptor characterization, ligand profiling, potency determination, lead optimization, and high-throughput screening applications supporting metabolic disease and neuroscience drug discovery programs.

Applications of the AMY3 Stable Cell Line

• AMY3 receptor pharmacology studies
• Amylin signaling investigations
• Agonist and antagonist screening
• Obesity and weight management research
• Diabetes and metabolic disease drug discovery
• Neurodegenerative disease studies
• cAMP and calcium signaling assays
• High-throughput screening applications

Biological Significance of AMY3

AMY3 is an important component of the amylin signaling system that helps regulate glucose metabolism, energy balance, and appetite control. Activation of AMY3 contributes to satiety signaling, suppression of glucagon secretion, delayed gastric emptying, and improved postprandial glucose regulation. These physiological effects have made amylin receptor agonists valuable therapeutic tools in the management of diabetes and obesity. In addition to its metabolic functions, AMY3 signaling has been implicated in neuronal activity, cognitive function, and neurodegenerative disease mechanisms. Emerging research suggests that amylin receptor pathways may influence amyloid-related pathology and neuroinflammation, making AMY3 a growing area of interest in Alzheimer's disease research. Because of its dual relevance to metabolic and neurological disorders, AMY3 remains an important target for translational research and GPCR-focused drug discovery. The AMY3 Stable Cell Line provides a valuable tool for studying amylin receptor biology and advancing the development of next-generation therapeutics targeting obesity, diabetes, and neurodegenerative diseases.